RecruitingNCT04354064

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Sponsor

Washington University School of Medicine

Enrollment

100 participants

Start Date

May 29, 2019

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Esophageal Cancer Prostate Cancer Sarcoma Lung Cancer Melanoma Head and Neck Cancer Colon Cancer Gastrointestinal Cancer Skin Cancer Genitourinary Cancer Solid Tumor Cancer Healthy Volunteer

Summary

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood samples from healthy volunteers to develop and refine a blood test that detects tiny fragments of tumor DNA (called circulating tumor DNA or ctDNA) in cancer patients. Healthy donor samples are used as a baseline comparison to make the test more accurate. **You may be eligible if:** - You are a healthy adult aged 18 or older - You are willing to provide a blood sample for research **You may NOT be eligible if:** - You are younger than 18 years old Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.